The estimated monitoring rate of adults in the U.S. with CHB with at least an annual ALT and HBV DNA in individuals without cirrhosis is only 37%, with an estimated 59% receiving antiviral treatment when they become eligible for treatment [3]. The gene discussed is GPT; the disease is Cirrhosis.